<!DOCTYPE html>

<html lang="en">
<head>
<meta charset="utf-8"/>
<title>article276</title>
<style>
        body {
            font-family: Arial, sans-serif;
            margin: 0;
            padding: 0;
            background-color: #f3f3f3;
        }
        .container {
            max-width: 800px;
            margin: auto;
            background: #fff;
            padding: 20px;
            box-shadow: 0 0 10px rgba(0, 0, 0, 0.1);
        }
        h1, h2 {
            color: #333;
        }
        p {
            line-height: 1.6;
        }
        a {
            text-decoration: none;
            color: #5a5a5a;
        }
        a:hover {
            color: #000;
        }
    </style>
</head>
<body>
<div class="container"><p><a href="../index_gpt.html">Back to Index</a></p><li><a href="https://www.wikijournalclub.org/wiki/HEMO" style="display:block; margin-bottom:10px;">HEMO Original</a></li>
<h2><strong>HEMO</strong></h2>
<div class="container">
<h2><strong></strong></h2>
<div class="container">
<div class="container">
<h2><strong></strong></h2>
<h2><strong></strong></h2>

    "Dialysis Dose and the Effect of Membrane Flux in Maintenance Hemodialysis".The New England Journal of Medicine. 2002. 347(25):2010-2019.PubMed•Full text•PDF<br/>
<br/>
<h2><strong>Contents</strong></h2><br/>
1 Clinical Question<br/>
2 Bottom Line<br/>
3 Major Points<br/>
4 Guidelines<br/>
5 Design<br/>
6 Population<br/>
6.1 Inclusion Criteria<br/>
6.2 Exclusion Criteria<br/>
6.3 Baseline Characteristics<br/>
7 Interventions<br/>
8 Outcomes<br/>
8.1 Primary Outcome<br/>
8.2 Secondary Outcomes<br/>
9 Funding<br/>
10 Further Reading<br/>
<br/>
<h2><strong>Clinical Question</strong></h2><br/>
Among patients undergoing maintenance hemodialysis, does increasing the dose of dialysis or using a high-flux dialyzer membrane improve survival or reduce morbidity?<br/>
<br/>
<h2><strong>Bottom Line</strong></h2><br/>
Among patients undergoing maintenance hemodialysis, neither increased dose of dialysis beyond the current U.S. recommended levels nor the use of high-flux membranes substantially improves survival or reduces morbidity when compared to a standard dose and low-flux membranes.<br/>
<br/>
<h2><strong>Major Points</strong></h2><br/><br/>
<br/>
<h2><strong>Guidelines</strong></h2><br/>
Current U.S. practice guidelines recommend a single-pool Kt/V of at least 1.24 but do not specifically recommend for or against the routine use of high-flux membranes.<br/>
<br/>
<h2><strong>Design</strong></h2><br/>
Multicenter, double-blind, randomized, two-by-two factorial clinical trial<br/>
N=1,846 patients undergoing thrice-weekly in-center hemodialysis<br/>
Intervention groups:<br/>
Standard dose of dialysis (equilibrated Kt/V ~1.16) vs. high dose of dialysis (equilibrated Kt/V ~1.53)<br/>
Low-flux dialyzer (beta2-microglobulin clearance ~3 mL/min) vs. high-flux dialyzer (beta2-microglobulin clearance ~34 mL/min)<br/>
<br/>
<h2><strong>Population</strong></h2><br/>
Inclusion Criteria: Patients aged 18 to 80 undergoing thrice-weekly in-center hemodialysis for ≥3 months<br/>
Exclusion Criteria: Serum albumin &lt;2.6 g/dL, residual urea clearance &gt;1.5 mL/min per 35 liters or inability to achieve equilibrated Kt/V &gt;1.30 within 4.5 hours in test runs<br/>
Baseline Characteristics: Predominance of urban centers; high rates of hypertension (96%), diabetes (45%), and cardiac disease (80%)<br/>
<br/>
<h2><strong>Interventions</strong></h2><br/>
Randomized 1:1 ratio to either a standard-dose or high-dose goal and to dialysis with either a low-flux or high-flux dialyzer.<br/>
<br/>
<h2><strong>Outcomes</strong></h2><br/>
Primary Outcome:<br/>
Death from any cause: no significant difference between dose groups (RR 0.96, 95% CI 0.84 to 1.10, P=0.53) or between flux groups (RR 0.92, 95% CI 0.81 to 1.05, P=0.23)<br/>
Secondary Outcomes:<br/>
Hospitalizations for cardiac causes or death, hospitalizations for infection or death, decline in serum albumin levels or death, and hospitalizations not related to vascular access: no significant difference between dose or flux groups<br/>
Possible benefits of dose or flux interventions suggested in subgroups of patients<br/>
<br/>
<h2><strong>Funding</strong></h2><br/>
Supported by the National Institute of Diabetes and Digestive and Kidney Diseases with additional support from Baxter Healthcare, Fresenius Medical Care, R&amp;D Laboratories, and Ross Laboratories.<br/>
<br/>
<h2><strong>Further Reading</strong></h2><br/>
For additional information on the study and its implications, readers are directed to associated NEJM publications and the study's report in PubMed and other medical literature databases.
    <p></p>
</div>
</div>
</div>
</div>
</body>
</html>
